CLDX vs NKTR

For growth investors, Nektar Therapeutics (NKTR) is the stronger pick with -43.

9% revenue growth year-over-year, versus -78. 6% for Celldex Therapeutics, Inc. (CLDX). Analysts rate Celldex Therapeutics, Inc. (CLDX) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Celldex Therapeutics, Inc.

(CLDX) delivered a total return of +29. 4%, compared to -69. 4% for Nektar Therapeutics (NKTR). Over 10 years, the gap is even starker: CLDX returned -34. 3% versus NKTR's -57. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Celldex Therapeutics, Inc.

(CLDX) is the lower-risk stock at 1. 73β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 7% more volatile than CLDX relative to the S&P 500. On balance sheet safety, Celldex Therapeutics, Inc. (CLDX) carries a lower debt/equity ratio of 0% versus 95% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nektar Therapeutics (NKTR) is pulling ahead at -43.

9% versus -78. 6% for Celldex Therapeutics, Inc. (CLDX). On earnings-per-share growth, the picture is similar: Nektar Therapeutics grew EPS -12. 1% year-over-year, compared to -59. 2% for Celldex Therapeutics, Inc.. Over a 3-year CAGR, CLDX leads at -14. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nektar Therapeutics (NKTR) is the more profitable company, earning -297.

1% net margin versus -172. 5% for Celldex Therapeutics, Inc. — meaning it keeps -297. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NKTR leads at -253. 7% versus -191. 6% for CLDX. At the gross margin level — before operating expenses — CLDX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Celldex Therapeutics, Inc.

(CLDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CLDX: -34. 3%, NKTR: -57. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.